Judicious Use of Ozanimod for Ulcerative Colitis and Multiple Sclerosis

Abstract

Clinical trials have demonstrated the efficacy of ozanimod, an oral sphingosine-1-phosphate receptor modulator, for the treatment of moderate-to-severe ulcerative colitis. Infrequently does an opportunity present itself to use one drug for two simultaneous disease states, proving especially beneficial in the case of this patient intolerant of numerous established therapies for ulcerative colitis. This case report describes the successful use of ozanimod for both ulcerative colitis and multiple sclerosis, achieving clinical remission in both diseases.

Keywords: Ozanimod; inflammatory bowel disease; multiple sclerosis; sphingosine-1-phosphate receptor modulator; ulcerative colitis.